Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Abbvie inc. symbols : Gmab save search
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
research global leukemia therapeutics market
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Published: 2024-02-27 (Crawled : 01:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.28%
H: 1.46%
C: 1.46%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.6%
H: 1.11%
C: 0.41%
epkinly fda license review application
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
Published: 2024-01-04 (Crawled : 13:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.16%
H: 1.95%
C: 1.94%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 1.25%
H: 0.99%
C: 0.63%
conference abbvie
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.78%
H: 4.49%
C: 1.55%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.09%
H: 3.38%
C: 3.18%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.54%
H: 3.6%
C: 2.42%
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: -0.14%
H: 0.19%
C: -0.31%
conference abbvie
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Published: 2023-12-09 (Crawled : 20:20) - prnewswire.com
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
CERE | $42.15 0.02% 0.02% 810K
|
Finance
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody antibody treatment response
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody antibody
Genmab Announces Financial Results for the First Nine Months of 2023
Published: 2023-11-07 (Crawled : 16:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.39%
H: 4.92%
C: 1.52%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.18%
C: 0.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.24%
H: 3.44%
C: 2.07%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.35%
H: 3.09%
C: 3.03%
financial results
Genmab Announces Financial Results for the First Half of 2023
Published: 2023-08-03 (Crawled : 15:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.24%
H: 1.29%
C: 1.29%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.06%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -2.25%
H: 1.87%
C: 1.52%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.25%
H: 3.13%
C: 1.84%
financial results
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: -1.43%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Published: 2023-06-22 (Crawled : 11:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -4.0%
H: 5.18%
C: 5.18%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.21%
H: 0.55%
C: 0.19%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.73%
H: 1.53%
C: 1.48%
network guidelines cancer
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
Published: 2023-06-09 (Crawled : 07:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -3.3%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.06%
H: 1.18%
C: 0.45%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.44%
H: 0.18%
C: -0.44%
association lymphomas meeting program
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-05-19 (Crawled : 16:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.61%
H: 1.26%
C: 1.24%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.29%
H: 1.35%
C: 0.87%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.54%
H: 2.0%
C: 1.81%
drug antibody approved food
Genmab Announces Financial Results for the First Quarter of 2023
Published: 2023-05-10 (Crawled : 14:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.92%
H: 0.54%
C: -0.64%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.24%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.03%
H: 0.26%
C: 0.01%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.09%
H: 0.48%
C: 0.28%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.21%
H: 0.32%
C: -0.07%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.15%
H: 2.12%
C: 1.79%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.6%
H: 1.64%
C: -0.39%
financial results
Genmab Publishes 2022 Annual Report
Published: 2023-02-22 (Crawled : 17:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.51%
H: 1.17%
C: -0.9%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.98%
H: 0.03%
C: -1.06%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.32%
H: 0.22%
C: -0.45%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.66%
H: 0.76%
C: -0.22%
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: -1.33%
H: 4.88%
C: 2.2%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.53%
H: 0.32%
C: -2.74%
report
Medikine Appoints Roland Buelow, Ph.D., to Board of Directors
Published: 2022-12-06 (Crawled : 17:00) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.15%
H: 1.16%
C: -0.9%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.64%
H: 0.04%
C: -2.12%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -0.19%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.49%
H: 0.12%
C: -2.25%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: -2.98%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.11%
H: 0.02%
C: -1.74%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.48%
H: 1.59%
C: 0.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.33%
H: 0.56%
C: -0.89%
Cancer Monoclonal Antibodies Market Report 2022: Rising Preference for Personalized Medicines Provides Boost to Sector
Published: 2022-11-04 (Crawled : 18:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -2.57%
H: 3.43%
C: 2.04%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.13%
H: 0.63%
C: 0.53%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.25%
H: 0.03%
C: -0.78%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.42%
H: 0.59%
C: -0.04%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.64%
H: 0.16%
C: -0.05%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.58%
H: 0.93%
C: 0.93%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.48%
H: 2.81%
C: 2.71%
report cancer market
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-10-28 (Crawled : 13:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -4.93%
H: 2.09%
C: 1.15%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.03%
H: 1.82%
C: 1.82%
cd20 duobody treatment
Genmab Announces Financial Results for the First Half of 2022
Published: 2022-08-10 (Crawled : 15:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.39%
H: 5.07%
C: -0.05%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.0%
H: 0.01%
C: -0.67%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.47%
H: 0.11%
C: 0.02%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 2.33%
H: 0.64%
C: -0.72%
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.15%
H: 4.93%
C: 2.47%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.82%
H: 1.15%
C: -1.16%
cd20 duobody treatment application authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.